Danielle Roman, PharmD, BCOP
Articles by Danielle Roman, PharmD, BCOP
CDK4/6 Inhibitors in Visceral Crisis and in Patients With Positive Lymph Nodes
ByDanielle Roman, PharmD, BCOP, Jodi Taraba, PharmD, MS, BCOP,Heather Moore, BCOP, CPP, PharmD, Rose DiMarco, PharmD, BCPS, BCOP Panelists discuss how CDK4/6 inhibitors can be considered for patients with visceral crisis based on limited data from the RIGHT Choice trial (though historically chemotherapy has been preferred), and how the number of positive lymph nodes in early-stage breast cancer drives treatment selection based on the specific inclusion criteria from the monarchE and NATALEE trials, with dual-eligible patients requiring consideration adverse effect profiles and patient-specific factors.
FDA-Approved CDK4/6 Inhibitors for Early and Metastatic Breast Cancer
ByDanielle Roman, PharmD, BCOP, Jodi Taraba, PharmD, MS, BCOP,Heather Moore, BCOP, CPP, PharmD, Rose DiMarco, PharmD, BCPS, BCOP Panelists discuss how FDA-approved CDK4/6 inhibitors are used in early breast cancer (abemaciclib and ribociclib with different trial designs and dosing regimens) and metastatic breast cancer (palbociclib, ribociclib, and abemaciclib showing approximately 2-year progression-free survival advantages in various combination therapies).
